Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancerSep 8Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines to lease four Redwood City buildings for new HQSep 1FinancingRevolution Medicines, Inc.
Johns Hopkins registers Phase 2 trial of Revolution Medicines' daraxonrasib in biliary tract cancerAug 28Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLCAug 20Trial updateRevolution Medicines, Inc.zoldonrasib
Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasibAug 10Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Summit reports Q2 2026 results as HARMONi OS data hold up in western patientsJul 23Clinical readoutGlaxoSmithKlineivonescimab
Sign in